You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,066,269


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,066,269
Title:Methods for detecting and treating multiple myeloma
Abstract: The invention provides methods for using the expression levels and subcellular localization of non-coding mitochondrial RNAs to select individuals or subpopulation of individuals for treatment with an anticancer therapy for multiple myeloma. Additional methods provided herein are useful for determining whether an individual in remission for multiple myeloma following successful treatment will be likely to suffer a relapse as well as to identify individuals who have suffered a relapse of multiple myeloma.
Inventor(s): Villota Arcos; Claudio E. (Santiago, CL), Villegas Olavarria; Jaime E. (Santiago, CL), Burzio Menendez; Veronica A. (Santiago, CL), Burzio Eriz; Luis O. (Santiago, CL)
Assignee: ANDES BIOTECHNOLOGIES GLOBAL, INC. (Burlingame, CA)
Application Number:14/776,260
Patent Claims:1. A method for treating relapsed multiple myeloma in an individual thereof comprising: treating the individual with one or more anti-cancer therapeutics, wherein prior to treatment plasmocytes isolated from the bone marrow of the individual exhibit (i) nuclear or (ii) cytoplasmic and nuclear subcellular localization, but do not exhibit solely cytoplasmic subcellular localization of a sense non-coding mitochondrial RNA (SncmtRNA), wherein the one or more anti-cancer therapeutics is radiotherapy, chemotherapy, a monoclonal antibody, one or more oligonucleotides sufficiently complementary to a human non-coding mitochondrial chimeric RNA molecule, a hormone treatment, or a combination thereof the non-coding mitochondrial chimeric RNA molecule comprising a. an antisense 16S mitochondrial ribosomal RNA covalently linked at its 5' end to the 3' end of a polynucleotide with an inverted repeat sequence or b. a sense 16S mitochondrial ribosomal RNA covalently linked at its 5' end to the 3' end of a polynucleotide with an inverted repeat sequence, wherein the oligonucleotides are able to hybridize with the mitochondrial chimeric RNA molecules to form a stable duplex.

2. The method of claim 1, wherein the anti-cancer therapeutics comprise remicade, docetaxel, celecoxib, melphalan, dexamethasone (Decadron.RTM.), gemcitabine, cisplatinum, temozolomide, etoposide, cyclophosphamide, temodar, carboplatin, procarbazine, gliadel, topotecan, methotrexate, taxol, taxotere, fluorouracil, irinotecan, xeloda, CPT-11, interferon alpha, pegylated interferon alpha (e.g., PEG INTRON-A), capecitabine, cisplatin, thiotepa, fludarabine, carboplatin, liposomal daunorubicin, cytarabine, doxetaxol, pacilitaxel, vinblastine, dacarbazine, vinorelbine, zoledronic acid, palmitronate, busulphan, prednisone, bortezomib (Velcade.RTM.), arsenic trioxide, vincristine, doxorubicin (Doxil.RTM.), paclitaxel, adriamycin, estrainustine sodium phosphate (Emcyt.RTM.), and etoposide.

3. The method of claim 1, wherein the anti-cancer therapy is administered as part of a salvage therapy in treating patients wherein the multiple myeloma has become refractory to other drugs.

4. The method of claim 1, wherein the method further comprises administering one or more additional therapies.

5. The method of claim 4, wherein the one or more additional therapies comprise stem cell transplant therapy.

6. The method of claim 1, wherein the SncmtRNA comprises a human mitochondrial chimeric RNA molecule comprising a sense 16S mitochondrial ribosomal RNA covalently linked at its 5' end to the 3' end of a polynucleotide with an inverted repeat sequence.

7. The method of claim 1, wherein the SncmtRNA comprises one or more nucleotide sequences selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.

8. The method of claim 1, wherein the multiple myeloma relapsed after treatment with one or more of bortezomib (Velcade.RTM.), cyclophosphamide, dexamethasone, doxorubicin, interferon-alpha, lenalidomide, melphalan, pegylated interferon-alpha, prednisone, thalidomide, and vincristine.

9. The method of claim 1, wherein the subcellular localization of the SncmtRNA or ASncmtRNA is measured by in situ hybridization.

10. A method for treating relapsed multiple myeloma in an individual thereof comprising: treating the individual with one or more anti-cancer therapeutics, wherein prior to treatment plasmocytes isolated from the bone marrow of the individual exhibit (i) nuclear or (ii) cytoplasmic and nuclear subcellular localization, but do not exhibit solely cytoplasmic subcellular localization of a sense non-coding mitochondrial RNA (SncmtRNA), wherein the one or more anti-cancer therapeutics is high-dose chemotherapy with autologous or allogenic hematopoietic stem-cell transplantation.

Details for Patent 10,066,269

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2033-03-14
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2033-03-14
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2033-03-14
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 08/24/1998 ⤷  Try a Trial 2033-03-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.